Freedom Wealth Alliance’s Standard BioTools LAB Stock Holding History

Freedom Wealth Alliance’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$59.1K	Buy	+20,394	New	+$53.3K	0.1%	43

Other funds holding LAB

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Freedom Wealth Alliance's LAB Position: Q3 2023 in Review

Freedom Wealth Alliance opened a new position in Standard BioTools (LAB) in Q3 2023: 20,394 shares worth $59.1K. The stake represents 0.1% of the portfolio and ranks #43 among its holdings.

72 funds tracked by Wall St. Rank hold LAB as of Q3 2023.

Freedom Wealth Alliance held 20,394 shares of Standard BioTools worth $59.1K as of Q3 2023.
Standard BioTools was a new Freedom Wealth Alliance position in Q3 2023.
Standard BioTools made up 0.1% of Freedom Wealth Alliance's portfolio in Q3 2023, its #43 holding.
72 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2023.

Based on Freedom Wealth Alliance's 13F filing for Q3 2023, filed 30 Oct 2023.